Brief: Deutsche Biotech Innovativ Says Adrenomed's Antibody Adrecizumab From Shows Positive Effect In COVID-19 Patients
25/08/2020 10:00
Aug 25 (Reuters) - DEUTSCHE BIOTECH INNOVATIV AG DBIG.F :
* BARRIER FUNCTION OF BLOOD VESSELS AS THERAPEUTIC TARGET IN
LIFE-THREATENING COVID-19 PATIENTS: ADRENOMED'S ANTIBODY
ADRECIZUMAB FROM SHOWS POSITIVE EFFECT
Source text for Eikon: ID:nEQygWZ0a
Further company coverage: DBIG.F
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Deutsche Biotech Innovativ AG
See all newsBrief: Deutsche Biotech Innovativ Positive Results Of Phase II Study Adrenomed Adrenoss-2
Brief: Deutsche Biotech Innovativ Says Adrenomed's Antibody Adrecizumab From Shows Positive Effect In COVID-19 Patients
Brief: Deutsche Biotech Innovativ Signs Convertible Loan Agreement With SphingoTec
Brief: Deutsche Biotech Innovativ: Three Main Shareholders Divest Up To 15% Of Shares
Brief: Deutsche Biotech Innovativ Appoints Ralf M. Jakobs As New CFO